I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.
Benzotropine methanesulfonate is used to treat the symptoms of Parkinson?s disease and is currently in clincial trials for chronic back pain. It shows anti-muscarinic effects comparable to Atropine, and also demonstrates competitive anti-nicotinic action at the nAChR (nicotinic acetylcholine receptor).
Heidi Bisgaard; M Andreas B Larsen; Sonia Mazier; Thijs Beuming; Amy Hauck Newman; Harel Weinstein; Lei Shi; Claus J Loland; Ulrik Gether. The binding sites for benztropines and dopamine in the dopamine transporter overlap. Neuropharmacology. 2011, 60, (1), 182-190.
José A G Agúndez; Elena García-Martín; Hortensia Alonso-Navarro; Félix Javier Jiménez-Jiménez. Anti-Parkinson's disease drugs and pharmacogenetic considerations. Expert Opinion on Drug Metabolism and Toxicology. 2013, 9, (7), 859-874.
Hazard Statements: H301-H311-H331
Toxic if swallowed. Toxic in contact with skin. Toxic if inhaled.
Precautionary Statements: P261-P280h-P301+P310a-P304+P340-P405-P501a
Avoid breathing dust/fume/gas/mist/vapours/spray. Wear protective gloves/clothing. IF SWALLOWED: IF INHALED: Remove to fresh air and keep at rest in a position comfortable for breathing. Store locked up. Dispose of contents/container in accordance with local/regional/national/international regulations.